entertainment -WSS

entertainment

author：focus 2025-09-29 13:31:23 - browse：52

Medicare generally pays far more for CAR-T drugs that are administered in outpatient departments than it does for inpatient care. Adobe

WASHINGTON — Hospitals for years have complained that Medicare pays so little for CAR-T cancer treatments that they sometimes lose money administering the incredibly expensive treatments. But that could soon change: if drug companies succeed in making the cancer treatments safer, hospitals could provide them more often in outpatient departments, where payment is higher.

CAR-T uses the body’s own immune system to kill cancerous cells. The procedure, regulated as a drug, involves taking T cells from a patient’s blood, adding chimeric antigen receptors (CAR) to the T cells that kill cancer, and injecting the CAR-T treatment back into the patient.

It’s worked wonders in many cancer patients who have run out of options. But right now it’s almost exclusively administered in hospitals, because the side effects can require aggressive treatments. In many cases, the CAR-T cells trigger immune reactions that can be life-threatening.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Breakthrough Alzheimer’s drugs are inaccessible in rural states

WSS

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

Lawsuit alleges UnitedHealth Group unit illegally denied claims

Micronoma's microbiome cancer diagnostic approach under fire

Why Sanofi got shellacked over its spinoff

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Vertex non

explore

entertainment

entertainment

How one medical school became remarkably diverse

The high personal cost of affirmative action for Black doctors

United colonoscopy coverage change 'may cost lives,' doctors say

WHO may add ‘noma' to its list of neglected tropical diseases

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

NIH launches clinical trials and new research office for long Covid

Bright Health sells Medicare Advantage business to Molina

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Cassava reveals details — and problems — with Alzheimer's study

focus

What to expect as Trump is arraigned on his Jan 6. indictment

Chimpanzees, like humans and whales, get menopause: Study

Why Sanofi got shellacked over its spinoff

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

What to expect as Trump is arraigned on his Jan 6. indictment

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

entertainment

focus

focus

entertainment